- by sedlv
- January 5, 2024
Newly established relationship with Cystic Fibrosis Foundation enables clinical studies targeting cystic fibrosis-associated infections
(January 5, 2024) | By Kellie Hotz, Clarametyx Biosciences.
COLUMBUS, Ohio – January 5, 2024 – Clarametyx Biosciences, Inc. (“Clarametyx”), a clinical stage company developing targeted, immune-enabling biologic therapies to counter persistent infections associated with biofilms, today announced the successful completion of a $33 million Series A round. The proceeds from the round will enable the company to accelerate efforts across its pipeline, including specifically to evaluate the potential of Clarametyx’s lead therapeutic candidate CMTX-101 to combat infection in people with cystic fibrosis (CF), a progressive, genetic disease that affects the lungs, pancreas and other organs.
Clarametyx was launched in 2020 to advance a novel, immune-enabling antibody technology licensed from Nationwide Children’s Hospital. The powerful non-antibiotic and pathogen-agnostic approach is designed to target and remove universal structural elements within the bacterial biofilm, with the goal of rapid biofilm collapse that renders bacteria vulnerable to immune or antibiotic intervention. The company is evaluating its anti-biofilm technology in both therapeutic and preventive settings to address the global challenge of persistent bacterial infection and antibiotic resistance.